CN107810192A - 非天然的脑信号蛋白3及其医药用途 - Google Patents

非天然的脑信号蛋白3及其医药用途 Download PDF

Info

Publication number
CN107810192A
CN107810192A CN201680011456.5A CN201680011456A CN107810192A CN 107810192 A CN107810192 A CN 107810192A CN 201680011456 A CN201680011456 A CN 201680011456A CN 107810192 A CN107810192 A CN 107810192A
Authority
CN
China
Prior art keywords
seq
semaphorin
amino acid
nucleic acid
mutated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680011456.5A
Other languages
English (en)
Chinese (zh)
Inventor
奎多·瑟瑞尼
恩里科·吉拉尔多
卢卡·塔玛诺尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piemonte Oncology Foundation
Original Assignee
Seagull Treatment Simple Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagull Treatment Simple Stock Co filed Critical Seagull Treatment Simple Stock Co
Publication of CN107810192A publication Critical patent/CN107810192A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
CN201680011456.5A 2015-02-23 2016-02-23 非天然的脑信号蛋白3及其医药用途 Pending CN107810192A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15156195.8 2015-02-23
EP15156195 2015-02-23
PCT/EP2016/053750 WO2016135130A1 (en) 2015-02-23 2016-02-23 Non-natural semaphorins 3 and their medical use

Publications (1)

Publication Number Publication Date
CN107810192A true CN107810192A (zh) 2018-03-16

Family

ID=52596769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680011456.5A Pending CN107810192A (zh) 2015-02-23 2016-02-23 非天然的脑信号蛋白3及其医药用途

Country Status (12)

Country Link
US (1) US10906948B2 (https=)
EP (1) EP3262064A1 (https=)
JP (1) JP6959869B2 (https=)
KR (1) KR20170138410A (https=)
CN (1) CN107810192A (https=)
AU (1) AU2016223584B2 (https=)
BR (1) BR112017017825A2 (https=)
CA (1) CA2976593A1 (https=)
IL (1) IL253872B (https=)
RU (1) RU2722832C2 (https=)
SG (1) SG11201706211PA (https=)
WO (1) WO2016135130A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109821009A (zh) * 2019-01-22 2019-05-31 南京医科大学 轴突导向因子重组蛋白Semaphorin3G的医药用途
CN110684805A (zh) * 2019-11-19 2020-01-14 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
WO2021068962A1 (zh) * 2019-10-11 2021-04-15 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
CN112687338A (zh) * 2020-12-31 2021-04-20 云舟生物科技（广州）有限公司 基因序列的存储和还原方法、计算机存储介质及电子设备
CN115947817A (zh) * 2023-02-22 2023-04-11 广州庆毅生物医药科技有限公司 一种肿瘤相关多肽及其制备方法和应用
CN116650481A (zh) * 2021-12-10 2023-08-29 中南大学湘雅医院 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用
CN116790610A (zh) * 2023-05-18 2023-09-22 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
CN119464491A (zh) * 2024-10-28 2025-02-18 中山大学 circSEMA3C编码SEMA-123aa在膀胱癌淋巴转移靶向治疗中的作用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017000059A1 (en) 2015-06-29 2017-01-05 The University Of British Columbia B1sp fusion protein therapeutics, methods, and uses
EP3321683A4 (en) * 2015-07-09 2018-11-21 Juntendo Educational Foundation Method for evaluating lymph node metastatic potential of endometrial cancer
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
CN111009287B (zh) * 2019-12-20 2023-12-15 东软集团股份有限公司 SLiMs预测模型的生成方法、装置、设备和存储介质
WO2021245670A1 (en) * 2020-06-04 2021-12-09 Medical Research & Development Fund for Health Services Bnai Zion Medical Center Modified semaphorin 3a, compositions comprising the same and uses thereof
AU2022415337A1 (en) * 2021-12-14 2024-08-01 Daniel Pierce RADIN Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
US5639856A (en) * 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
EP1216258A1 (en) 1999-09-28 2002-06-26 Universität Zürich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7290975B2 (en) 2001-03-17 2007-11-06 Mechanical Tech & Engineering Co. Two-speed passenger lift and pump assembly therefor
US7781413B2 (en) 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
US7184284B2 (en) 2004-03-30 2007-02-27 Micron Technology, Inc. Closed-loop high voltage booster
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
SG178744A1 (en) * 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
EP2781223B1 (en) * 2007-10-19 2017-02-22 Rappaport Family Institute for Research in the Medical Sciences Compositions comprising semaphorins for use in the treatment of cancer
WO2011066284A1 (en) * 2009-11-25 2011-06-03 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of immune disorders
EP3677310A1 (en) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109821009A (zh) * 2019-01-22 2019-05-31 南京医科大学 轴突导向因子重组蛋白Semaphorin3G的医药用途
WO2021068962A1 (zh) * 2019-10-11 2021-04-15 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
CN114466859A (zh) * 2019-10-11 2022-05-10 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
CN114466859B (zh) * 2019-10-11 2024-12-20 田中纯美 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
CN110684805A (zh) * 2019-11-19 2020-01-14 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN112687338A (zh) * 2020-12-31 2021-04-20 云舟生物科技（广州）有限公司 基因序列的存储和还原方法、计算机存储介质及电子设备
CN116650481A (zh) * 2021-12-10 2023-08-29 中南大学湘雅医院 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用
CN115947817A (zh) * 2023-02-22 2023-04-11 广州庆毅生物医药科技有限公司 一种肿瘤相关多肽及其制备方法和应用
CN116790610A (zh) * 2023-05-18 2023-09-22 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
CN119464491A (zh) * 2024-10-28 2025-02-18 中山大学 circSEMA3C编码SEMA-123aa在膀胱癌淋巴转移靶向治疗中的作用

Also Published As

Publication number Publication date
SG11201706211PA (en) 2017-09-28
WO2016135130A1 (en) 2016-09-01
JP6959869B2 (ja) 2021-11-05
RU2017128465A (ru) 2019-03-25
US10906948B2 (en) 2021-02-02
IL253872A0 (en) 2017-10-31
US20180030100A1 (en) 2018-02-01
AU2016223584A1 (en) 2017-08-17
JP2018506994A (ja) 2018-03-15
BR112017017825A2 (pt) 2018-04-10
IL253872B (en) 2021-04-29
RU2017128465A3 (https=) 2019-07-24
CA2976593A1 (en) 2016-09-01
KR20170138410A (ko) 2017-12-15
RU2722832C2 (ru) 2020-06-04
EP3262064A1 (en) 2018-01-03
AU2016223584B2 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
US10906948B2 (en) Non-natural Semaphorins 3 and their medical use
CN109618556B (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
JP6316195B2 (ja) モノクローナル抗体および使用の方法
US20250042957A1 (en) Designed repeat domains with dual binding specificity and their use
TW201716442A (zh) 抗EphA4抗體
CN110997714A (zh) 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
CN112105629A (zh) 调节性t细胞表面抗原的表位以及与其特异性结合的抗体
KR20240115192A (ko) 조절 t 세포 표면 항원 및 이에 특이적으로 결합하는 항체
EP1567545B1 (en) Peptides and their use in the treatment of central nervous system damage
HK1245304A1 (en) Non-natural semaphorins 3 and their medical use
EP3216458A1 (en) Modified vascular endothelial growth factor a (vegf-a) and its medical use
EP3145545B1 (en) Bak binding proteins
RU2395522C1 (ru) Наноантитело v93, связывающее vegf, и способ его получения, кодирующая v93 нуклеотидная последовательность и содержащий ее вектор, способ ингибирования пролиферации эндотелиальных клеток
MC MK et al. Förderung der Wissenschaften eV 80539 München (DE)
Serini et al. Medical use of combinations of non-natural semaphorins 3 and antimetabolites
KR20260026033A (ko) 항-원섬유 항체
WO2019207051A1 (en) Medical use of combinations of non-natural semaphorins 3 and antimetabolites
Serini et al. Non-natural Semaphorins 3 and their medical use
JP2022501062A (ja) Ｅｐｎ１を標的とする抗体
HK40058922A (en) Antibodies targeting epn1
KR20190107967A (ko) 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법
JPWO2001079478A1 (ja) マスト細胞脱顆粒反応に関与する因子およびそれらをコードするｄｎａ、並びに該因子に対する阻害剤のスクリーニング法および該阻害剤
HK1149031A (en) Peptide capable of binding to immunoglobulin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1245304

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230616

Address after: Italy Tori

Applicant after: Guido Sarini

Applicant after: Enrico Geraldo

Applicant after: Luca Tamanoni

Address before: Lower Rhine, France

Applicant before: Seagull Therapeutics S.A.S.

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1245304

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250416

Address after: Torino

Applicant after: Piemonte oncology Foundation

Country or region after: Italy

Address before: Italy Tori

Applicant before: Guido Sarini

Country or region before: Italy

Applicant before: Enrico Geraldo

Applicant before: Luca Tamanoni